title: Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment.
abstract: OBJECTIVE
  Although the benefit of cardiac resynchronization therapy (CRT) in selected patients with heart failure is well established, its effect on mortality in New York Heart Association (NYHA) class IV patients remains unclear. Our study evaluated the effect of CRT on urgent transplant-free survival in NYHA class IV patients treated with CRT, compared with medication-only treatment.
  
  
  RESULTS
  Forty NYHA class IV patients treated with CRT (80% men, 62.5% ischaemic, mean age of 65) were matched 1:1 by age, gender and aetiology of cardiomyopathy with patients treated with optimal medical therapy (OPT group). No significant differences were found between the groups in left ventricular diastolic diameter (71 +/- 6 vs. 73 +/- 9 mm), left ventricular systolic diameter (58 +/- 7 vs. 61 +/- 11 mm), and left ventricular ejection fraction (23 +/- 5 vs. 22 +/- 6%). Mean follow-up was 13.2 +/- 9.5 months for the CRT group and 17.3 +/- 11.6 months for the OPT group. Time to all-cause death or urgent transplantation [hazard ratios (HR), 1.29; 95% CI: 0.59-2.83; P = 0.52] or to cardiovascular death or urgent transplantation (HR, 1.53; 95% CI: 0.64-3.67; P = 0.34) was not reduced significantly in patients treated with CRT.
  
  
  CONCLUSIONS
  In this study, CRT did not significantly improve survival of NYHA class IV heart failure patients compared with pharmacological therapy.
authors.affiliation: Thorax Clinic Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Villarroel 170, Barcelona 08036, Spain. macastel@clilnic.ub.es
authors.forename: María Angeles
authors.initials: MA
authors.lastname: Castel
authors.forename: Santiago
authors.initials: S
authors.lastname: Magnani
authors.forename: Lluís
authors.initials: L
authors.lastname: Mont
authors.forename: Eulalia
authors.initials: E
authors.lastname: Roig
authors.forename: David
authors.initials: D
authors.lastname: Tamborero
authors.forename: Francisco
authors.initials: F
authors.lastname: Méndez-Zurita
authors.forename: José Francisco
authors.initials: JF
authors.lastname: Femenia
authors.forename: José María
authors.initials: JM
authors.lastname: Tolosana
authors.forename: Félix
authors.initials: F
authors.lastname: Pérez-Villa
authors.forename: Josep
authors.initials: J
authors.lastname: Brugada
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial / Q000401:mortality* / Q000706:statistics & numerical data*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D016027:Heart Transplantation / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009518:New York / Q000453:epidemiology; D012720:Severity of Illness Index; D012955:Societies, Medical
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics